Clinical trials: Intestinal Transplantation
Clostridium Difficile Infection Recurrence
A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection
This trial will be initiated to explore whether RBX2660 (REBYOTA®) could be suitable for administration by the practice of colonoscopy.
- Trial name
- CDI-SCOPE (NCT05831189)
- Testing
- RBX2660
- Where
- 12 sites in United States
- Volunteers
- 41 people
- Sponsor
- Ferring Pharmaceuticals
Diverticulitis, Colonic, Colon Inflamed
Fecal Transplantation in Patients Colonic Diverticulitis
The goal of this clinical trial is to investigate the safety and effect of fecal microbiome transplantation (FMT) in patients with a former episode of acute colonic diverticulitis.
- Trial name
- NCT06254625
- Testing
- Fecal Microbiome
- Where
- Denmark
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Odense University Hospital
Parkinson Disease
Fecal Microbiota Transplantation for Parkinson's Disease
Parkinson's disease (PD) is the second most common neurodegenerative disorder and due to the lack of early diagnosis and effective therapy, represents a large burden for our society and healthcare system.
- Trial name
- NCT03808389
- Testing
- Donor FMT, Autologous FMT
- Where
- Belgium
- Volunteers
- 49 people
- Sponsor
- University Ghent
Acute Myeloid Leukemia, Graft-versus-host-disease
Changes in the Gut Microbiota of Patients Undergoing Allogeneic Stem Cell Transplantation (COLLECT)
COLLECT is a monocentric, prospective, observational study, which aims to assess the association between changes in the intestinal microbiota and the incidence of gastrointestinal graft-versus-host diseases (GvHD).
- Conditions
- Acute Myeloid Leukemia, Graft-versus-host-disease, Allogeneic Hematopoietic Stem Cell Transplantation, Stem Cell Transplant Complications
- Trial name
- COLLECT (NCT03148197)
- Where
- Germany
- Volunteers
- 120 people
- Sponsor
- University of Cologne
Acute Myeloid Leukemia With FLT3/ITD Mutation, Allogeneic Hematopoietic Stem Cell Transplantation
The Gut Microbiome and Sorafenib Maintenance Therapy in FLT3-ITD Positive AML After Allo-HSCT
This prospective trial investigates the effect of sorafenib maintenance therapy in FLT3-ITD positive AML patients after allo-HSCT in terms of gut microbiome.
- Trial name
- NCT05596968
- Testing
- Sorafenib
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Leukemia, Lymphoma
Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment
RATIONALE: Everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer.
- Conditions
- Leukemia, Lymphoma, Lymphoproliferative Disorder
- Trial name
- NCT00436618
- Testing
- Everolimus
- Where
- 3 sites in United States
- Volunteers
- 277 people
- Sponsor
- Mayo Clinic
Colorectal Cancer, Liver Metastases
Living Donor Liver Transplantation for Unresectable Colorectal Cancer Liver Metastases
Patients with unresectable liver metastases (LM) from colorectal cancer (CRC)have a poor prognosis. In patients with resectable disease, surgery offers a distinct survival benefit.
- Trial name
- NCT02864485
- Testing
- live donor liver transplantation
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University Health Network, Toronto
Primary Sclerosing Cholangitis (PSC), Inflammatory Bowel Disease (IBD)
Fecal Microbiota Transplantation for Primary Sclerosing Cholangitis - Randomized Study Versus Sham Transplantation
Primary Sclerosing Cholangitis (PSC) is a rare cholestatic liver disease, commonly associated with inflammatory bowel disease (IBD) The aim of the present trial is to assess the efficacy of fecal microbiota transplantation (FMT)…
- Trial name
- FMT-SCLER (NCT07477782)
- Testing
- Fecal microbiota transplantation (FMT)
- Where
- France
- Volunteers
- 72 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Amyotrophic Lateral Sclerosis ALS
Intestinal Microbiome Transplant in ALS
This is a 24-week study of intestinal microbiome transplant in people with ALS. All participants will be evaluated clinically in person for 4 visits. Blood and mailed/ fresh stool samples will also be collected.
- Trial name
- NCT07017946
- Testing
- MTP-101C
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Duke University
Cirrhosis, Liver
Study on Effect of Intestinal Microbiota Transplantation in Hepatitis B Virus Induced Cirrhosis
Chronic hepatitis B (CHB) is a common infectious disease affecting up to 2 billion people worldwide. Around 650 thousand people died of liver failure, cirrhosis and primary liver cancer caused by chronic hepatitis B every year.
- Trial name
- NCT03437876
- Testing
- intestinal microbiota transplant
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Zhongshan Hospital Xiamen University
Liver Disease; Alcohol-Related, Cirrhosis
Intestinal Microbiota Transplant in Alcohol-Associated Liver Disease
The purpose of this research study is to test the safety, tolerability, and effectiveness of the capsules that contain bacteria from healthy individuals when used to treat alcohol craving and drinking.
- Conditions
- Liver Disease; Alcohol-Related, Cirrhosis, Alcohol Use Disorder
- Trial name
- IMPACT (NCT05548452)
- Testing
- Intestinal Microbiota Transplant (IMT) Capsules
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Virginia Commonwealth University
Irritable Bowel Syndrome
Effects of Faecal Microbiota Transplantation in Patients With IBS
Irritable bowel syndrom (IBS) is a common chronic gastrointestinal disorder that affects 10-20% of the world population. The prevalence of IBS in Norway is between 8% and 25%.
- Trial name
- NCT03822299
- Testing
- healthy feces microbiota
- Where
- Norway
- Volunteers
- 164 people
- Sponsor
- Helse Fonna
Coronary Artery Disease, Type 2 Diabetes Mellitus (T2DM)
Effects of Fecal Microbiota Transplantation in Patients With Type 2 Diabetes and Coronary Artery Disease (CAD-Microbiome) - A Pilot Study
This pilot study investigates whether fecal microbiota transplantation (FMT) can modify the gut microbiome in patients with type 2 diabetes mellitus and stable coronary artery disease (CAD).
- Trial name
- CAD-Microbiome (NCT07421947)
- Testing
- Fecal Microbiota Transplantation
- Where
- Switzerland
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Zurich
Intestinal Graft Dysfunction
Endoscopically One-year Follow-up in Patients After Small-bowel Transplantation
Intestinal transplantation is associated with high numbers of ejection events. A close endoscopic controll of the intestinal graft is possible. Sasaki et al.
- Trial name
- NCT04633486
- Testing
- zoom-endoscopy
- Where
- Germany
- Volunteers
- 15 people
- Sponsor
- University Hospital Tuebingen
Autism Spectrum Disorder, Gastro-Intestinal Disorder
Microbiota Transplant Therapy for Children With Both Autism Spectrum Disorder and Gastrointestinal Disorders
The investigators propose to investigate Microbiota Transfer Therapy (MTT) for treating patients with Autism-spectrum disorder with Gastrointestinal disorders (constipation, diarrhea, and/or abdominal pain).
- Conditions
- Autism Spectrum Disorder, Gastro-Intestinal Disorder, Constipation, Diarrhea
- Trial name
- NCT06503978
- Testing
- MTP-101P, Vancomycin, Miralax
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Gut-Brain-Axis Therapeutics Inc.
Stem Cell Transplant Complications, Acute Graft-Versus-Host Disease
FMT for Steroid Resistant Gut Acute GVHD
The study aims to evaluate the safety and efficacy of fecal microbiota transplantation (FMT) for the treatment of steroid resistant graft-versus-host-disease (GVHD) of the gut.
- Conditions
- Stem Cell Transplant Complications, Acute Graft-Versus-Host Disease, Fecal Microbiota Transplantation
- Trial name
- NCT04285424
- Testing
- Fecal Microbiota Transplantation
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Affiliated Hospital to Academy of Military Medical Sciences
Resilience, Cognitive Function and Well-Being
Aging Resilience Through Microbiota Optimization and Regulation
Sarcopenia, characterized by the progressive loss of muscle mass and strength in older adults, is a key factor in health deterioration.
- Conditions
- Resilience, Cognitive Function and Well-Being, Muscle Function, Handgrip Strength Test, Insulin Sensitivity
- Trial name
- ARMOR (NCT06649981)
- Testing
- FMT capsule
- Where
- 2 sites in Chile
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Gonzalo Jorquera, PhD
Transplant;Failure,Kidney, Transplant; Failure, Liver
Abdominal Wall Transplant
The purpose of this protocol is to determine the safety and efficacy of abdominal wall transplantation as a treatment for the reconstruction of abdominal wall defects.
- Conditions
- Transplant;Failure,Kidney, Transplant; Failure, Liver, Transplant; Failure, Bowel, Abdominal Wall Defect
- Trial name
- NCT03310905
- Testing
- Abdominal Wall Transplant with another solid organ transplant, Abdominal Wall Transplant alone
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Duke University
Autism Spectrum Disorder
Application of Esketamine in Anesthesia of Autism Children
Autism Spectrum Disorder (ASD) is a group of serious neurodevelopmental disorders. Autistic children appear with significant frequency for medical services, lots of which requiring procedural sedation or anaesthesia.
- Trial name
- NCT05960942
- Testing
- propofol combined with esketamine, propofol-sufentanil
- Where
- China
- Volunteers
- 120 people
- Sponsor
- The Second Hospital of Nanjing Medical University
Recurrent C. Difficile (rCDI), Ulcerative Colitis (UC)
Multi-omics Dissection of Gut Microbiome Engraftment During FMT
The gut microbiota plays a key role in immunity and metabolism and contributes to diseases such as recurrent C. difficile infection (rCDI), ulcerative colitis (UC), and metabolic syndrome (MetS).
- Conditions
- Recurrent C. Difficile (rCDI), Ulcerative Colitis (UC), Metabolic Syndrome (MetS)
- Trial name
- DissEcT (NCT06992453)
- Testing
- Fecal microbiota transplantation (FMT)
- Where
- Italy
- Volunteers
- 90 people
- Sponsor
- Catholic University of the Sacred Heart